New Approaches for the Treatment of Alzheimer’s Disease
Open accessAbstract
Alzheimer's disease (AD) is the most prevalent chronic neurodegenerative disease. Current approved therapies are symptomatic treatments having some effect on cognitive function. Therapies that target β-amyloid (Aβ) have been the focus of efforts to develop a disease modification treatment for AD but these approaches have failed to show any clinical benefit so far. Beyond the 'Aβ hypothesis', there are a number of newer approaches to treat AD with neuroinflammation emerging as a very active area of research based on risk gene analysis. This short review will summarize approved drug therapies, recent clinical trials and new approaches for the treatment of AD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Current AD drug treatments have only partial and temporary effectiveness and affect only the consequences of AD rather than the cause.
“However, these treatments, whose effectiveness is only partial and temporary at best, affect only the consequences of AD rather than the cause [1,17,157,158].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [17]
The Approved Therapies section says current approved treatments are symptomatic, have some effect on cognition, and do not directly target AD pathology. It does not establish that their effectiveness is only temporary: it describes long-term benefits as debatable and notes that some studies report long-term efficacy. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredCurrent drug treatments for Alzheimer's disease have only symptomatic effects, and disease-modifying treatments are not yet available.
“Indeed, current drug treatments have only symptomatic effects, and disease-modifying treatments are not yet available.”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [17]
Immunotherapy is being used to develop anti-amyloid and anti-tau agents, and alternative strategies targeting misfolded tau proteins and neuronal regeneration are under investigation.
“Apart from the drugs mentioned above, immunotherapy is being made use of to develop anti-amyloid and anti-tau agents, also alternative strategies targeting the misfolded tau proteins and neuronal regeneration are under investigation [98].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · see citing works
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894 · see citing works
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,644 · see citing works
Lane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616 · see citing works
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918 · see citing works
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912 · see citing works
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · see citing works
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · see citing works
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · see citing works
Human Memory and the Cholinergic System
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,398 · see citing works
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · see citing works
Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., Yu, O., Crane, P. K., & Larson, E. B. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7663 · Cited by 1,111 · see citing works
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 3× · see citing works
“Despite enrolling greater patient numbers than the previous two EXPEDITION trials, in late 2016 it was reported that EXPEDITION 3 had failed to meet its primary endpoint, with results published in early 2018 showing solanezumab treatment having no positive effect on cognitive decline.(34)”
ResultInfluentialBiomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000 · see citing works
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909 · see citing works
The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725 · see citing works
Readhead, B., Haure-Mirande, J.-V., Funk, C. C., Richards, M. A., Shannon, P., Haroutunian, V., Sano, M., Liang, W. S., Beckmann, N. D., Price, N. D., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.023 · Cited by 708 · see citing works
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697 · see citing works
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685 · see citing works
Chen, H., Pellegrini, J. W., Aggarwal, S., Lei, S., Warach, S. J., Jensen, F., & Lipton, S. A. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 630 · see citing works
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565 · see citing works
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547 · see citing works
Hansen, R. A., Webb, A. P., Moore, C. G., Gartlehner, G., Jonas, D. E., & Morgan, L. C. (2020) · PubMed Central · doi:10.17615/ae8c-2p76 · Cited by 523 · see citing works
DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516 · see citing works
Drug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459 · see citing works
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 440 · see citing works
Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427 · see citing works
Webster, L., Groskreutz, D., Grinbergs‐Saull, A., Howard, R. J., O'Brien, J. T., Mountain, G. A., Banerjee, S., Woods, B. T., Perneczky, R., Lafortune, L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179521 · Cited by 415 · see citing works
The amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402 · see citing works
Kennedy, M., Stamford, A., Chen, X., Cox, K., Cumming, J., Dockendorf, M., Egan, M. F., Ereshefsky, L., Hodgson, R., Hyde, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 391 · see citing works
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387 · see citing works
Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease
Liguori, C., Romigi, A., Nuccetelli, M., Zannino, S., Sancesario, G., Martorana, A., Albanese, M., Mercuri, N. B., Izzi, F., Bernardini, S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2510 · Cited by 355 · see citing works
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 334 · see citing works
Elucidating the Role of TREM2 in Alzheimer’s Disease
Ulrich, J. D., Ulland, T. K., Colonna, M., & Holtzman, D. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.042 · Cited by 325 · see citing works
<scp>F</scp>yn inhibition rescues established memory and synapse loss in <scp>A</scp>lzheimer mice
Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314 · see citing works
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Cummings, J. (2018) · Clinical and Translational Science · doi:10.1111/cts.12491 · Cited by 298 · see citing works
Bakker, A., Albert, M., Krauss, G. L., Speck, C. L., & Gallagher, M. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.02.009 · Cited by 284 · see citing works
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
Farlow, M. R., Arnold, S. E., van Dyck, C. H., Aisen, P. S. S., Snider, B. J., Porsteinsson, A. P., Friedrich, S. W., Dean, R. A., Gonzales, C., Sethuraman, G., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.224 · Cited by 280 · see citing works
Karran, E. H., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 275 · see citing works
Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease
Villegas-Llerena, C., Phillips, A., Garcia-Reitboeck, P., Hardy, J., & Pocock, J. M. (2016) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.10.004 · Cited by 270 · see citing works
Kook, S.-H., Hong, H. S., Moon, M., Ha, C. M., Chang, S., & Mook‐Jung, I. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.6102-11.2012 · Cited by 267 · see citing works
The serotonergic system in ageing and Alzheimer's disease
Rodriguez, J. J., Noristani, H. N., & Verkhratsky, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.010 · Cited by 266 · see citing works
Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · see citing works
Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Neumann, K., Rojo, L., Navarrete, L., Farias, G., Reyes, P., & Maccioni, R. (2008) · Current Alzheimer Research · doi:10.2174/156720508785908919 · Cited by 236 · see citing works
Feldman, H., Gauthier, S. G., Hecker, J. R., Vellas, B. J., Emir, B., Mastey, V., Subbiah, P., & The Donepezil MSAD Study Investigators Group (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1365-2389.2003.51260.x · Cited by 202 · see citing works
Alzheimer and his disease: a brief history
Cipriani, G., Dolciotti, C., Picchi, L., & Bonuccelli, U. (2010) · Neurological Sciences · doi:10.1007/s10072-010-0454-7 · Cited by 195 · see citing works
Calcium, free radicals and excitotoxins in neuronal apoptosis
Lipton, S. A., & Nicotera, P. (1998) · Cell Calcium · doi:10.1016/s0143-4160(98)90115-4 · Cited by 188 · see citing works
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177 · see citing works
Atri, A., Frölich, L., Ballard, C. G., Tariot, P. N., Molinuevo, J. L., Boneva, N., Windfeld, K., Rakêt, L. L., & Cummings, J. L. (2018) · JAMA · doi:10.1001/jama.2017.20373 · Cited by 167 · see citing works
Wilkinson, D. G., Windfeld, K., & Colding‐Jørgensen, E. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70198-x · Cited by 164 · see citing works
Update on the Pharmacological Treatment of Alzheimers Disease
Massoud, F., & Gauthier, S. G. (2010) · Current Neuropharmacology · doi:10.2174/157015910790909520 · Cited by 161 · see citing works
Genetics of Alzheimer's Disease
Guerreiro, R. J., & Hardy, J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0295-9 · Cited by 158 · see citing works
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Burstein, A. H., Grimes, I., Galasko, D. R., Aisen, P. S. S., Sabbagh, M. N., & Mjalli, A. M. M. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-12 · Cited by 137 · see citing works
Wattmo, C., Wallin, A., Londos, E., & Minthon, L. (2010) · The Gerontologist · doi:10.1093/geront/gnq050 · Cited by 125 · see citing works
Maher‐Edwards, G., Zvartau-Hind, M. E., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., Davy, M., & Williams, P. M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383831 · Cited by 117 · see citing works
The role of 5 HT6-receptor antagonists in Alzheimer’s disease: an update
Khoury, R., Grysman, N., Gold, J., Patel, K., & Grossberg, G. T. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1483334 · Cited by 115 · see citing works
Timmers, M., Streffer, J. R., Russu, A., Tominaga, Y., Shimizu, H., Shiraishi, A., Tatikola, K., Smekens, P., Börjesson-Hanson, A., Andreasen, N., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0415-6 · Cited by 112 · see citing works
Distinct Therapeutic Mechanisms of Tau Antibodies
Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., & Diamond, M. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657924 · Cited by 111 · see citing works
Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs
Yan, R. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0061-5 · Cited by 100 · see citing works
Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease
Wang, C. Y., Finstad, C. L., Walfield, A. M., Sia, C., Sokoll, K. K., Chang, T.-Y., Fang, X. D., Hung, C. H., Hutter-Paier, B., & Windisch, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.031 · Cited by 98 · see citing works
Simmons, D. A., Knowles, J. K., Belichenko, N. P., Banerjee, G., Finkle, C., Massa, S. M., & Longo, F. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102136 · Cited by 97 · see citing works
Mo, J., Li, J., Yang, Z., Liu, Z., & Feng, J. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.469 · Cited by 92 · see citing works
Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present
Yasmin, S., & Jayaprakash, V. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.020 · Cited by 90 · see citing works
Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84 · see citing works
Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation
Meneses, A. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00316-8 · Cited by 80 · see citing works
Impaired peripheral glucose homeostasis and Alzheimer's disease
Wijesekara, N., Gonçalves, R. A., Felice, F. G. D., & Fraser, P. E. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.027 · Cited by 80 · see citing works
Classics in Chemical Neuroscience: Memantine
Alam, S., Lingenfelter, K. S., Bender, A. M., & Lindsley, C. W. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00270 · Cited by 73 · see citing works
Using genetics to enable studies on the prevention of Alzheimer's disease
Crenshaw, D. G., Gottschalk, W. K., Lutz, M. W., Grossman, I., Saunders, A. M., Burke, J. R., Welsh-Bohmer, K. A., Brannan, S. K., Burns, D. K., & Roses, A. D. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.222 · Cited by 70 · see citing works
A review of the effects of memantine on clinical progression in Alzheimer's disease
Wilkinson, D. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2788 · Cited by 69 · see citing works
Memantine ER/Donepezil: A Review in Alzheimer’s Disease
Greig, S. L. (2015) · CNS Drugs · doi:10.1007/s40263-015-0287-2 · Cited by 69 · see citing works
Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?
Bali, P., Lahiri, D. K., Banik, A., Nehru, B., & Anand, A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314145347 · Cited by 63 · see citing works
What Do We Know About Behavioral Crises in Dementia? A Systematic Review
Backhouse, T., Camino, J., & Mioshi, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170679 · Cited by 52 · see citing works
Adler, G., Mueller, B., & Articus, K. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12374 · Cited by 47 · see citing works
Teich, A. F., Sharma, E., Barnwell, E., Zhang, H., Staniszewski, A., Utsuki, T., Padmaraju, V., Mazell, C., Τζέκου, Α., Sambamurti, K., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.12.001 · Cited by 44 · see citing works
Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis.
Kitten, A., Hallowell, S. A., Saklad, S. R., & Evoy, K. E. (2018) · PubMed Central · Cited by 40 · see citing works
Moschetti, V., Schlecker, C., Wind, S., Goetz, S., Schmitt, H., Schultz, A., Liesenfeld, K., Wunderlich, G. R., & Desch, M. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0660-2 · Cited by 33 · see citing works
Microglia-targeted candidates push the Alzheimer drug envelope
Mullard, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.65 · Cited by 31 · see citing works
BACE failures lower AD expectations, again
Mullard, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.94 · Cited by 29 · see citing works
Yilmaz, T., Jutten, R. J., Santos, C. Y., Hernandez, K. A., & Snyder, P. J. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.005 · Cited by 24 · see citing works
The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer’s Disease
Ghosh, A. K., Cárdenas, E. L., & Osswald, H. L. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2016_16 · Cited by 23 · see citing works
On the origin of transformative drugs
Mullard, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.95 · Cited by 19 · see citing works
Forester, B. P., Romano, C., Quayle, W., Georgakas, J. E., & Rosenberg, P. B. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.1839 · Cited by 6 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- [3]3. a) Lane, C. A., Hardy, J., Schott J. M. Alzheimer's disease. Eur. J. Neurol. 2018, 25, 59-70.
- [13]13. Gray, S. L. et al. Cumulative Use of Strong Anticholinergics and Incident Dementia. JAMA Intern. Med. 2015, 175, 401-407.
- [68]68. In first phase 3 trial, the tau drug LMTM did not work. Period. ALZFORUM NEWS, 29 th July 2016. See: 'https://www.alzforum.org/news/conference-coverage/first-phase-3-trial-tau-drug- lmtm-did-not-work-period'. Accessed 5 th October 2018.
- [73]73. Kaufman, A. C., Salazar, S. V., Haas, L.T., et al. Fyn Inhibition Rescues Established Memory and Synapse Loss in Alzheimer Mice. Ann. Neurol. 2015, 77, 953-971.
Cited by
Sorted by citations
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820 · see citing works
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 592 · see citing works
Alzheimer’s Disease: An Update and Insights Into Pathophysiology
Abubakar, M. B., Sanusi, K. O., Ugusman, A., Mohamed, W. M. Y., Kamal, H., Ibrahim, N. H., Khoo, C. S., & Kumar, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.742408 · Cited by 293 · see citing works
Applications of fluorine-containing amino acids for drug design
Mei, H., Han, J., Klika, K. D., Izawa, K., Sato, T., Meanwell, N. A., & Soloshonok, V. A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111826 · Cited by 249 · see citing works
Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Athar, T., Balushi, K. A. A., & Khan, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06512-9 · Cited by 261 · see citing works
Mitochondrial dynamics and transport in Alzheimer's disease
Flannery, P. J., & Trushina, E. V. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.06.009 · Cited by 198 · see citing works
Jahangard, Y., Monfared, H., Moradi, A., Zare, M., Mirnajafi‐Zadeh, J., & Mowla, S. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00564 · Cited by 169 · see citing works
Mast Cells in Stress, Pain, Blood-Brain Barrier, Neuroinflammation and Alzheimer’s Disease
Kempuraj, D., Mentor, S., Thangavel, R., Ahmed, M. E., Selvakumar, G. P., Raikwar, S. P., Dubova, I., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00054 · Cited by 135 · see citing works
Fard, M. T., & Stough, C. K. K. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00056 · Cited by 121 · see citing works
Blaikie, L., Kay, G., & Lin, P. K. T. (2019) · MedChemComm · doi:10.1039/c9md00337a · Cited by 113 · see citing works
Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
Pais, M. V., Martinez, L. D., Ribeiro, O. G., Loureiro, J. C., Fernandez, R., Valiengo, L. D. C. L., Canineu, P. R., Stella, F., Talib, L. L., Radanovic, M., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0735 · Cited by 118 · see citing works
Gonçalves, P. B., Sodero, A. C. R., & Cordeiro, Y. (2021) · Biomolecules · doi:10.3390/biom11050767 · Cited by 115 · see citing works
Synthesis and applications of mirror-image proteins
Harrison, K., Mackay, A. S., Kambanis, L., Maxwell, J. W. C., & Payne, R. J. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00493-y · Cited by 104 · see citing works
GPS driving: a digital biomarker for preclinical Alzheimer disease
Bayat, S., Babulal, G. M., Schindler, S. E., Fagan, A. M., Morris, J. C., Mihailidis, A., & Roe, C. M. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00852-1 · Cited by 91 · see citing works
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Vogt, A. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 86 · see citing works
Jiang, Y., Liu, C., Zhai, W., Zhuang, N., Han, T., & Ding, Z. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s214657 · Cited by 71 · see citing works
Dysregulated Wnt Signalling in the Alzheimer’s Brain
Aghaizu, N. D., Jin, H., & Whiting, P. J. (2020) · Brain Sciences · doi:10.3390/brainsci10120902 · Cited by 70 · see citing works
Self-citationCarbohydrate polymer-based nanoparticle application in drug delivery for CNS-related disorders
Ansari, R., Sadati, S. M., Mozafari, N., Ashrafi, H., & Azadi, A. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.109607 · Cited by 69 · see citing works
The amyloid precursor protein: a converging point in Alzheimer’s disease
Delport, A., & Hewer, R. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02863-x · Cited by 48 · see citing works
N-alkylpiperidine carbamates as potential anti-Alzheimer’s agents
Košak, U., Strašek, N., Knez, D., Jukič, M., Žakelj, S., Zahirović, A., Pišlar, A. H., Brazzolotto, X., Nachon, F., Kos, J., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112282 · Cited by 61 · see citing works
Advances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology
Hassan, N. A., Alshamari, A. K., Hassan, A. A., Elharrif, M. G., Alhajri, A. M., Sattam, M., & Khattab, R. R. (2022) · Molecules · doi:10.3390/molecules27154839 · Cited by 64 · see citing works
Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges
Iqbal, I., Saqib, F., Mubarak, Z., Latif, M. F., Wahid, M., Nasir, B., Shahzad, H., Sharifi-Rad, J., & Mubarak, M. S. (2024) · European Journal of Medical Research · doi:10.1186/s40001-024-01915-3 · Cited by 60 · see citing works
Serum neurofilament light chain level as a predictor of cognitive stage transition
Lee, E.-H., Kwon, H. S., Koh, S., Choi, S. H., Jin, J.-H., Jeong, J. H., Jang, J., Park, K. W., Kim, E., Kim, H. J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00953-x · Cited by 58 · see citing works
Statins and cognition: Modifying factors and possible underlying mechanisms
Jamshidnejad-Tosaramandani, T., Kashanian, S., Al-Sabri, M. H., Kročianová, D., Clemensson, L. E., Gentreau, M., & Schiöth, H. B. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.968039 · Cited by 59 · see citing works
Hydrogel, Electrospun and Composite Materials for Bone/Cartilage and Neural Tissue Engineering
Niemczyk-Soczynska, B., Zaszczyńska, A., Zabielski, K., & Sajkiewicz, P. (2021) · Materials · doi:10.3390/ma14226899 · Cited by 57 · see citing works
Hajinejad, M., Ghaddaripouri, M., Dabzadeh, M., Forouzanfar, F., & Negah, S. S. (2020) · BioMed Research International · doi:10.1155/2020/1034325 · Cited by 56 · see citing works
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 62 · see citing works
Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease
Martins, M., Silva, R., Pinto, M. M. M., & Sousa, E. (2020) · Pharmaceuticals · doi:10.3390/ph13090242 · Cited by 53 · see citing works
Chen, H., Chen, J., Li, J., Huang, H.-J., Chen, X., Zhang, H.-Y., & Chen, C. Y. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00041 · Cited by 49 · see citing works
Mutual population-shift driven antibody-peptide binding elucidated by molecular dynamics simulations
Bekker, G., Fukuda, I., Higo, J., & Kamiya, N. (2020) · Scientific Reports · doi:10.1038/s41598-020-58320-z · Cited by 48 · see citing works
Rabal, O., Sánchez-Arias, J. A., Cuadrado‐Tejedor, M., de Miguel, I., Pérez-González, M., García, C., Ugarte, A., de Mendoza, A. E., Sáez, E., Espelosin, M., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00303 · Cited by 46 · see citing works
Çakmak, R., Başaran, E., & Şentürk, M. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202100430 · Cited by 46 · see citing works
Dendrimers in Neurodegenerative Diseases
Pérez‐Carrión, M. D., & Posadas, I. (2023) · Processes · doi:10.3390/pr11020319 · Cited by 44 · see citing works
Yeh, T.-C., Kuo, C.-T., & Chou, Y.-B. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.860759 · Cited by 43 · see citing works
Sethi, P., Bhaskar, R., Singh, D. K. K., Gupta, S., Han, S. S., Avinash, D., Abomughaid, M. M., Koul, A., Rani, B., Ghosh, S., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102411 · Cited by 43 · see citing works
Kang, B. W., Kim, F., Cho, J., Kim, S., Rhee, J., & Choung, J. J. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01034-3 · Cited by 41 · see citing works
Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review
Sree, R. R., Kalyan, M., Anand, N., Mani, S., Gorantla, V. R., Sakharkar, M. K., Song, B., & Chidambaram, S. B. (2025) · ACS Omega · doi:10.1021/acsomega.4c05527 · Cited by 45 · see citing works
Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer’s disease
Latimer, C. S., & Liachko, N. F. (2021) · GeroScience · doi:10.1007/s11357-021-00407-0 · Cited by 39 · see citing works
Khan, S. A., Hussain, R., Khan, Y., Iqbal, T., Khan, M. B., Al‐Ahmary, K. M., & AL-Mhyawi, S. R. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138845 · Cited by 38 · see citing works
Ujan, R., Saeed, A., Channar, P. A., Larik, F. A., Abbas, Q., Alajmi, M. F., El-Seedi, H. R., Rind, M. A., Hassan, M., Raza, H., et al. (2019) · Molecules · doi:10.3390/molecules24050860 · Cited by 38 · see citing works
Recent Studies on Berry Bioactives and Their Health-Promoting Roles
Sarıcaoğlu, B., Erskine, E., Subaşı, B. G., & Çapanoğlu, E. (2021) · Molecules · doi:10.3390/molecules27010108 · Cited by 37 · see citing works
Panyatip, P., Padumanonda, T., Yongram, C., Kasikorn, T., Sungthong, B., & Puthongking, P. (2022) · Molecules · doi:10.3390/molecules27154979 · Cited by 37 · see citing works
Modeling Neurodegenerative Diseases Using In Vitro Compartmentalized Microfluidic Devices
Miny, L., Maisonneuve, B. G. C., Quadrio, I., & Honegger, T. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.919646 · Cited by 36 · see citing works
Borbély, E., Varga, V. É., Szögi, T., Schuster, I., Bozsó, Z., Penke, B., & Fülöp, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052514 · Cited by 34 · see citing works
Ailioaie, L. M., Ailioaie, C., & Litscher, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030916 · Cited by 37 · see citing works
Blaikie, L., Kay, G., & Lin, P. K. T. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127505 · Cited by 32 · see citing works
Sasi, V. M., Vangavolu, P., Kumar, S., & Raja, A. S. (2019) · ChemMedChem · doi:10.1002/cmdc.201900277 · Cited by 31 · see citing works
Terpenes as Potential Anti-Alzheimer’s Disease Agents
Lima, E., & Medeiros, J. (2024) · Applied Sciences · doi:10.3390/app14093898 · Cited by 30 · see citing works
Recent Studies on Heterocyclic Cholinesterase Inhibitors Against Alzheimer's Disease
Tok, F. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402837 · Cited by 30 · see citing works
Firouraghi, N., Kiani, B., Tabatabaei‐Jafari, H., Learnihan, V., Salinas-Pérez, J. A., Raeesi, A., Furst, M. A., Salvador‐Carulla, L., & Bagheri, N. (2022) · International Journal of Health Geographics · doi:10.1186/s12942-022-00308-1 · Cited by 33 · see citing works
Shi, X., Dong, L., Zhang, R., Zhou, D., Ling, S., Shao, L., Yan, Y. N., Wang, Y. X., & Wei, W. B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1174984 · Cited by 27 · see citing works
Handa, M., Sanap, S. N., Bhatta, R. S., Patil, G. P., Ghose, S., Singh, D. P., & Shukla, R. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213663 · Cited by 27 · see citing works
Huang, Y.-Y., Fang, N., Luo, H., Gao, F., Zou, Y., Zhou, L., Zeng, Q.-P., Fang, S.-S., Xiao, F., & Zheng, Q. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108304 · Cited by 26 · see citing works
Antioxidant, antimicrobial and neuroprotective effects of Octaviania asterosperma in vitro
Sevindik, М., Akgül, H., Selamoğlu, Z., & Braidy, N. (2020) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2020.1816584 · Cited by 26 · see citing works
Marine Organisms as Alkaloid Biosynthesizers of Potential Anti-Alzheimer Agents
Lima, E., & Medeiros, J. (2022) · Marine Drugs · doi:10.3390/md20010075 · Cited by 28 · see citing works
Huang, Y., Huang, W., Yang, G., Wang, R., & Ma, L. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128092 · Cited by 26 · see citing works
Baazaoui, N., & Iqbal, K. (2022) · Biomolecules · doi:10.3390/biom12101409 · Cited by 25 · see citing works
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
Adem, M. A., Decourt, B., & Sabbagh, M. N. (2024) · Biomedicines · doi:10.3390/biomedicines12010099 · Cited by 25 · see citing works
Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy
Mahboob, A., Ali, H., Naimi, A. J. A., Yousef, M., Rob, M., Al-Muhannadi, N. A., Senevirathne, D. K. L., & Châari, A. (2024) · Cells · doi:10.3390/cells13181527 · Cited by 25 · see citing works
Du, H., Jiang, X., Ma, M., Xu, H., Liu, S., & Ma, F. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127659 · Cited by 24 · see citing works
Senevirathne, D. K. L., Mahboob, A., Zhai, K., Paul, P., Kammen, A., Lee, D. J., Yousef, M. S., & Châari, A. (2023) · Cells · doi:10.3390/cells12111478 · Cited by 24 · see citing works
Handa, M., Sanap, S. N., Bhatta, R., Patil, G. P., Palkhade, R., Singh, D. P., & Shukla, R. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00454 · Cited by 22 · see citing works
Zarini-Gakiye, E., Amini, J., Sanadgol, N., Vaezi, G., & Kazem, P. (2020) · Current Molecular Pharmacology · doi:10.2174/1874467213666200422090135 · Cited by 22 · see citing works
Qiu, W., Liu, H., Liu, Y., Lü, X., Wang, L., Hu, Y., Feng, F., Li, Q., & Sun, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21947 · Cited by 20 · see citing works
Waseem, R., Shamsi, A., Khan, T., Hassan, M. I., Kazim, S. N., Shahid, M., & Islam, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115965 · Cited by 20 · see citing works
Păunescu, H., Dima, L., Ghiţă, I., Coman, L., Ifteni, P. I., Fulga, I., & Coman, O. A. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001120 · Cited by 19 · see citing works
Flavonoids as Promising Multitarget Agents in Alzheimer’s Disease Therapy
Lima, E., Rauter, A. P., & Medeiros, J. (2023) · Applied Sciences · doi:10.3390/app13084651 · Cited by 17 · see citing works
Sadoughi, D. (2019) · Comparative Clinical Pathology · doi:10.1007/s00580-019-02981-4 · Cited by 17 · see citing works
Karataş, H., Kul, İ. B., Aydin, M., Tüzün, B., Taslımı, P., & Kökbudak, Z. (2025) · Korean Journal of Chemical Engineering · doi:10.1007/s11814-025-00433-0 · Cited by 16 · see citing works
An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-β1
Song, G., Yang, H., Shen, N., Pham, P., Brown, B., Lin, X., Hong, Y., Paul, S., Cai, J., Li, X., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200413 · Cited by 15 · see citing works
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac123.28002812 · Cited by 15 · see citing works
Sabbagh, M. N., Cummings, J. L., Ballard, C. G., van der Flier, W. M., Heneka, M. T., Holst, J. J., Knudsen, L. B., Salloway, S., Tansey, M. G., & Drucker, D. J. (2025) · Nature Aging · doi:10.1038/s43587-025-01029-3 · Cited by 14 · see citing works
Hawash, Z. A. S., Yassien, E. M., Alotaibi, B. S., Elmoslemany, A. M., & Shukry, M. (2023) · Toxics · doi:10.3390/toxics11060509 · Cited by 14 · see citing works
Tang, D., Sun, C., Yang, J., Fan, L., & Wang, Y.-G. (2023) · Life · doi:10.3390/life13112203 · Cited by 16 · see citing works
Li, Y., Kang, M., Wang, H., He, J., Wang, X., Gan, W., Zhao, M., Zhao, X. Q., Wang, R., & Han, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190401 · Cited by 14 · see citing works
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13 · see citing works
Singh, S. K., Parihar, S., Jain, S., Ho, J. A., & Vankayala, R. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00578c · Cited by 12 · see citing works
Zhang, D., Wang, X., Li, R., Wang, L., Zhou, Z., Fu, Q., Cao, Y., & Fang, M. (2020) · Planta Medica · doi:10.1055/a-1212-3212 · Cited by 12 · see citing works
Angiotensin (1–7) Expressing Probiotic as a Potential Treatment for Dementia
Hernandez, A. R., Banerjee, A., Carter, C. S., & Buford, T. W. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.629164 · Cited by 12 · see citing works
Majid, H., & Silva, F. (2021) · Food and Bioproducts Processing · doi:10.1016/j.fbp.2021.04.018 · Cited by 12 · see citing works
The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro
Jamshidnejad-Tosaramandani, T., Kashanian, S., Babaei, M., Al-Sabri, M. H., & Schiöth, H. B. (2021) · Pharmaceuticals · doi:10.3390/ph14111136 · Cited by 12 · see citing works
Singh, G., Tamana, Devi, A., Saini, A., Thakur, Y., Khurana, S., Sharma, S., Diskit, T., & Singh, K. N. (2023) · Dyes and Pigments · doi:10.1016/j.dyepig.2023.111537 · Cited by 11 · see citing works
Rathee, S., Sen, D., Pandey, V., & Jain, S. (2024) · Current Drug Targets · doi:10.2174/0113894501320096240627071400 · Cited by 13 · see citing works
The Potential of cfDNA as Biomarker: Opportunities and Challenges for Neurodegenerative Diseases
Aydın, Ş., Özdemir, S., & Adıgüzel, A. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02317-8 · Cited by 11 · see citing works
Kim, J. H., Lee, H. S., Wee, J. H., Kim, Y. H., Min, C., Yoo, D. M., & Choi, H. G. (2021) · Brain Sciences · doi:10.3390/brainsci11030396 · Cited by 11 · see citing works
Grover, P., Rohilla, S., Bhardwaj, M., Mehta, L., & Malhotra, A. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230406084315 · Cited by 11 · see citing works
The endocrine pancreas of old obesehyperglycemic mice.
Westman, S. (1968) · PubMed · Cited by 11 · see citing works
Advancing Alzheimer's Therapy: Computational strategies and treatment innovations
Paul, J. K., Malik, A., Azmal, M., Gulzar, T., Afghan, M. T. R., Talukder, O. F., Shahzadi, S., & Ghosh, A. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.02.002 · Cited by 10 · see citing works
Monteiro, K. L. C., Alcântara, M. G. D. S., de Aquino, T. M., & da Silva‐Júnior, E. F. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200414164038 · Cited by 10 · see citing works
Early Chronic Stress Induced Changes within the Locus Coeruleus in Sporadic Alzheimer’s Disease
Minné, D., Marnewick, J. L., & Engel-Hills, P. C. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230811092956 · Cited by 9 · see citing works
Current trends and updates in the treatment of Alzheimer's disease
Parikh, N. H., Parikh, P. K., Rao, H. J., Shah, K., Dave, B. P., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00014-5 · Cited by 9 · see citing works
Recent advances in nanoenzymes for Alzheimer's disease treatment
Bi, X., Cao, N., & He, J. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114139 · Cited by 9 · see citing works
Siddiqui, F., Mishra, P., Khanam, S., Ranjan, S., Alam, P., Albalawi, T., Khan, S., & Mir, S. S. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70142 · Cited by 8 · see citing works
Szala‐Rycaj, J., Zagaja, M. P., Szewczyk, A., Polak, J., & Andres‐Mach, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080635 · Cited by 8 · see citing works
Tian, S., Liu, Y., Hong, H., & Li, S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05280-y · Cited by 8 · see citing works
O espectro clínico e laboratorial da doença de Alzheimer
Moreira, M. A., & Moreira, S. V. (2020) · Revista Psicologia em Pesquisa · doi:10.34019/1982-1247.2020.v14.30649 · Cited by 10 · see citing works
BANF1 promotes glutamate-induced apoptosis of HT-22 hippocampal neurons
Yao, X., Xu, X., Hu, K., Yang, Z., & Deng, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08889-1 · Cited by 8 · see citing works
A Review on the Use of Modern Computational Methods in Alzheimer’s Disease-Detection and Prediction
De, A., Mishra, T. K., Saraf, S., Tripathy, B. K., & Reddy, S. S. (2023) · Current Alzheimer Research · doi:10.2174/0115672050301514240307071217 · Cited by 8 · see citing works
Rothman, J. (2024) · Bilingualism Language and Cognition · doi:10.1017/s1366728924000026 · Cited by 8 · see citing works
Danappanvar, A. N., Biradar, P. R., Jalalpure, S. S., & Subhash, B. A. (2023) · Journal of Biophotonics · doi:10.1002/jbio.202300012 · Cited by 8 · see citing works
- Authors
- Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P.
- Affiliations
- The Francis Crick Institute (GB)
- Alzheimer’s Research UK (GB)
- Corresponding author
- Fish, Paul V.
- Venue
- Bioorganic & Medicinal Chemistry Letters
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 29
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0960-894X (ISSN-L)
- OpenAlex
- W2901817431
- Cited by
- 189
- References
- 83
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 34 · 2023: 32 · 2022: 33 · 2021: 20 · 2020: 22 · 2019: 13
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Licence
- Locations
- Bioorganic & Medicinal Chemistry Letters (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- UK Medical Research Council
- Alzheimer’s Research UK
- Francis Crick Institute
- Cancer Research UK (FC001002)
- Medical Research Council (FC001002)
- Wellcome Trust (FC001002)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, Alzheimer's disease treatment, amyloid-beta, amyloid hypothesis, disease-modifying therapy, neuroinflammation, risk genes, clinical trials, symptomatic treatment
- MeSH terms
- Alzheimer Disease, Animals, Humans, Amyloid beta-Peptides, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
